|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK.
|
31321612 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, this analysis provides support that variation in CYP19A1 may influence breast cancer risk differently in women with moderate to high NA ancestry.
|
25088806 |
2014 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Tamoxifen, raloxifene, and the aromatase inhibitors exemestane and anastrozole reduce invasive breast cancer in women without preexisting breast cancer, but also cause adverse effects that vary by medication.
|
31509915 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Additionally, we summarized breast cancer risk associated with the following genetic factors: breast cancer susceptibility high-penetrance genes (BRCA1, BRCA2, p53, PTEN, ATM, NBS1 or LKB1) and low-penetrance genes such as cytochrome P450 genes (CYP1A1, CYP2D6, CYP19), glutathione S-transferase family (GSTM1, GSTP1), alcohol and one-carbon metabolism genes (ADH1C and MTHFR), DNA repair genes (XRCC1, XRCC3, ERCC4/XPF) and genes encoding cell signaling molecules (PR, ER, TNFalpha or HSP70).
|
15784178 |
2005 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Ovarian function suppression (OFS) with tamoxifen or aromatase inhibitors (AIs) improves disease-free survival in premenopausal women with breast cancer, mostly in those at higher risk of recurrence.
|
31327728 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Urine prostaglandin E2 (PGE2) levels have shown to be a risk factor of breast cancer, and the use of nonsteroidal anti-inflammatory drugs (NSAIDs) is known to be beneficial in preventing breast cancer risk and/or recurrence with or without aromatase inhibitors.
|
28639029 |
2017 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Aromatase and breast cancer: W39R, an inactive protein.
|
11916629 |
2002 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The hypothesis tested in this study was that polymorphisms, or haplotypes, in CYP19 are related to risk of breast cancer.
|
17004113 |
2007 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study.
|
31292269 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In a multiethnic cohort study conducted in Los Angeles and on Hawaii we investigated (i) whether the plasma estrone to androstenedione (E1/A) ratio in different ethnic groups was associated with ethnic differences in breast cancer incidence, and (ii) whether genetic variation in the CYP19 gene encoding the P450 aromatase protein was associated with breast cancer risk.
|
10731105 |
1999 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genetic counselling and identification of high-risk families may be essential (1) to provide the best method for genetic testing by explaining the sensitivity and specificity of the methods, (2) to offer the opportunity to participate in specific early cancer detection programmes (breast (self) palpation, ultrasound, mammography and magnetic resonance tomography for breast cancer; vaginal exploration and ultrasound for ovarian cancer), (3) to inform them about prophylactic medication (oral contraceptive pill (OCP), chemoprevention (tamoxifen, raloxifen, aromatase inhibitors)) or surgery (bilateral prophylactic mastectomy or oophorectomy) and (4) to provide individualized psychological support.
|
10954253 |
2000 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We evaluate a series of polymorphisms of CYP19A1 and their effect on response to neoadjuvant letrozole in early BC.
|
20144226 |
2010 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patients with postmenopausal breast cancer (n = 20) treated with aromatase inhibitors and 20 age-matched control subjects.
|
30920624 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Marked cellular and molecular changes may occur in breast cancers following treatment of postmenopausal breast cancer patients with aromatase inhibitors.
|
16002280 |
2005 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The present case-control study aimed to investigate the main effect of polymorphisms in genes involved in xenobiotic metabolism and estrogen biosynthesis, CYP1A1, CYP1B1, COMT and CYP17, CYP19 and the BRCA1 founder mutation in relation to BC risk and to explore possible interactions between the gene polymorphisms and serum POP levels on BC risk in Greenlandic Inuit women.
|
24629213 |
2014 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We evaluated associations between CYP19 repeat alleles and breast cancer risk in a case-control study nested within the Nurses' Health Study cohort (incident cases: n=462; controls: n=618).
|
10861475 |
2000 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CYP19A1/rs3751591 was both associated with SHBG levels (P = 0.03) and with risk of BC (Incidence Rate Ratio = 2.12; 95 % Confidence Interval: 1.02-4.43) such that homozygous variant allele carriers had increased levels of serum SHBG and were at increased risk of BC.
|
27102200 |
2016 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We examined the association between CYP19A1 genetic polymorphisms and breast cancer survival in a cohort of 1,136 patients who were recruited as part of a population-based case-control study in Shanghai, China from 1996 to 1998 and who has donated a DNA sample to the study.
|
17119036 |
2006 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that the rs10046 polymorphism in the CYP19 gene may have an effect on breast cancer susceptibility at an age under 50 in the investigated population.
|
24402127 |
2014 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We can conclude that the rs10046 polymorphism on CYP19 by itself does not constitute breast cancer risk.
|
23342035 |
2013 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CYP19 (TTTA)7(-3bp) allele carriers showed a significantly (P<0.05) increased risk of ER-positive breast cancers (Odds Ratio (OR)=1.72, 95% Confidence Interval (CI) 1.10-2.69), but not ER-negative breast cancers.
|
14602139 |
2003 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A multigenic study on breast cancer risk associated with genetic polymorphisms of ER Alpha, COMT and CYP19 gene in BRCA1/BRCA2 negative Shanghai women with early onset breast cancer or affected relatives.
|
17562079 |
2007 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In a case-control study nested within a breast self-examination trial conducted in China, we examined whether CYP19A1 polymorphisms (rs1870049, rs1004982, rs28566535, rs936306, rs11636639, rs767199, rs4775936, rs11575899, rs10046, and rs4646) were associated with risk of breast cancer and fibrocystic breast conditions.
|
19064562 |
2008 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Oral endocrine therapy (OET) such as tamoxifen or aromatase inhibitors reduces recurrence and mortality for the 75% of breast cancer survivors (BCSs) with a diagnosis of estrogen receptor-positive breast cancer.
|
27532743 |
2018 |
|
Malignant neoplasm of breast
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole.
|
23129173 |
2013 |